PTCA球囊导管
Search documents
土耳其对原产于中国的“血管造影导管”和“PTCA球囊导管”产品启动反倾销调查
Shang Wu Bu Wang Zhan· 2025-11-27 23:32
11月26日,土耳其贸易部发布2025/38号公报,根据国内生产商艾维美迪卡医疗产品销售有限公司的申 请,并得到西梅克斯医疗产品商贸有限公司和阿尔法医疗化学化妆品医疗材料商贸有限公司的支持,决 定对原产于中国的"血管造影导管"和"PTCA球囊导管"产品启动反倾销调查,该产品归在海关税则 9018.39.00.00.29项下。 ...
金融“活水”润民企 农行浙江省分行民企贷款突破万亿元
Zhong Guo Jin Rong Xin Xi Wang· 2025-08-22 07:28
Core Insights - The Agricultural Bank of China Zhejiang Branch has become the first provincial branch in the country to surpass 1 trillion yuan in loans to private enterprises, reflecting its strong support for the growth of the private sector in Zhejiang [1][2] Group 1: Financial Support to Private Enterprises - The total amount of loans to private enterprises from the Agricultural Bank of China Zhejiang Branch has exceeded 1 trillion yuan, with nearly 3 trillion yuan in new loans issued over the past three years, serving over 360,000 private entities [1] - The bank has introduced several innovative financial products, including the largest single loan for equipment updates for a private enterprise and the first stock repurchase loan for a private enterprise within the Agricultural Bank system [2][3] Group 2: Support for International Expansion - The bank has facilitated the international expansion of private enterprises, exemplified by its support for Zhejiang New Australia Textile Co., Ltd. in establishing a production base in Vietnam with a fixed asset loan of 650 million yuan [2][3] - The bank has implemented 12 measures to support high-quality development of foreign trade and investment, benefiting over 20,000 outward-oriented private enterprises [3] Group 3: Digital Innovation in Financial Services - The Agricultural Bank of China Zhejiang Branch has developed a smart evaluation model to better match financial services with the needs of technology-driven enterprises, transitioning from traditional financial assessments to evaluating innovation and talent [3][4] - The bank has provided 10 million yuan in "Smart Technology Loans" to Zhejiang Batai Medical Technology Co., Ltd., addressing funding challenges for clinical trials of new medical devices [3][4]